5 mg/kg, iv infusion at weeks 0, 2, 6 and every 8 weeks through week 38
NAPSI-50 is achieved in 85% of patients at week 14, 96% at week 22, 98% at week 38; NAPSI-75 is achieved in 23% of patients at week 14, 65% at week 22, 81% at week 38; NAPSI-90 is achieved in 29% of patients at week 38
80 mg, sc at week 0, 40 mg every other week starting at week 1, through week 16; patients in the placebo group were started to receive active treatment starting at week 16, through week 28
Significantly higher improvement in NAPSI scores in the treatment arm (50% versus 8%) at week 16; once switched to adalimumab, patients in the initial placebo group improved 38% at week 28, while patients who began the study with adalimumab continued to improve to 54%
80 mg, sc at week 0, 40 mg every other week starting at week 1, through week 24
Significant improvement in all patients after 8th injection; fingernail NAPSI decreased from 11 at baseline to 4 at week 24 in patients with just cutaneous psoriasis and from 24 to 10 in patients with psoriatic arthritis
Significant improvements started as early as at week 14: 25% reduction in NAPSI scores in 50 mg group, 43% reduction in 100 mg group at week 14, 33% reduction in 50 mg, and 54% reduction in 100 mg group at week 24